The Anticipated Clinical Effect of the new Alzheimer drug ANAVEX 2-73 in a Calibrated Quantitative Systems Pharmacology Platform.
Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimer’s Disease
Chronic treatment with the tetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model.
Blockade of Tau Hyperphosphorylation and Ab1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and r1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease.
